To assess whether AKT pathway participates in IL-33-mediated cell cycle progression, we examined the expression levels of total AKT and phosphorylated AKT(Ser473) after treating the BM cells from ALL patients with IL-33, or in combination with SB203580 in culture for 72 h. The gene discussed is IL33; the disease is acute lymphoblastic leukemia.